spacer
home > ebr > winter 2018 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

This edition of EBR went to press just as a major breakthrough in the development of a potential treatment for Huntington’s disease was announced by researchers at University College London. Identifying, isolating and then being able to block synthesis of the defective, toxic proteins responsible for disease pathology has taken decades to accomplish, and a number of articles in our current issue resonate with aspects of this journey from gene to treatment. Although the exact neurological role of the Huntingtin gene product is not yet known, it is a complex, highly polymorphic protein and has the ability to identify even subtle changes from a core range of sequences, and structures of biological relevance through functional approaches such as microarrays could become increasingly valuable tools in disease research. The faulty Huntingtin gene responsible for Huntington’s disease was discovered in 1993.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Realising the potential of single-use technology – As published in Manufacturing Chemist

In this article Zenith Technologies’ Global Director of Managed Services David Staunton and Scott Ripley, Global Marketing Director at GE Healthcare, discuss the benefits and patient impact of single-use technology with Manufacturing Chemist.
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement